The addition of anti-CD96 in combination with anti-PD-1, anti-CTLA-4, anti-TIGIT, or doxorubicin chemotherapy resulted in superior antitumor responses by enhancing T-cell activity and suppressing tumor growth [102,103]. This evidence concerns the gene CTLA4 and neoplasm.